moc31-pe
mAbexperimentalADC
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2010 (NCT01061645)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Epithelial cell adhesion moleculeBINDING AGENT
EPCAM binding agent
- Epithelial cell adhesion moleculeINHIBITOR
EPCAM inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Pseudomonas exotoxin A
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109265 ↗
Also known as
- moc31-pe
- moc31-pe
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02219893 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2014 | Osaka University |
| NCT01061645 | Phase 1 | Sep 1, 2010 | Osaka University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Osaka University | Academic/Hospital | 2 | 2 | 2 | 2010 |
1 organizations
Page 1 / 1